Quarterly ResultJul 29, 2026, 07:10 AM
Axogen Q2 Revenue Up 23.1% to $69.7M; Reports $1.5M Net Loss
AI Summary
Axogen, Inc. reported strong second-quarter 2026 revenue of $69.7 million, a 23.1% increase year-over-year. Despite a GAAP net loss of $1.5 million, the company achieved an adjusted net income of $7.3 million. Axogen also highlighted significant business advancements, including the publication of the REPOSE clinical study, initiation of the Nerve-RESTORE study, and a minority investment in Trace Biosciences. The company reiterated its full-year 2026 financial guidance, expecting at least 24% revenue growth and positive free cash flow.
Key Highlights
- Revenue increased 23.1% to $69.7 million in Q2 2026, up from $56.7 million in Q2 2025.
- Reported a net loss of $1.5 million, or $0.03 per share, compared to net income of $0.6 million in Q2 2025.
- Adjusted net income was $7.3 million, or $0.12 per share, up from $5.7 million in Q2 2025.
- Cash and cash equivalents, restricted cash, and investments totaled $113.4 million as of June 30, 2026.
- Acquired a minority ownership stake in Trace Biosciences to support nerve-specific imaging technology.
- Published REPOSE study providing Level 1 evidence for Axoguard Nerve Cap for symptomatic neuroma management.
- Initiated Nerve-RESTORE study comparing Avance Nerve Graft to sural nerve autograft.
- Reaffirmed 2026 financial guidance for full-year revenue growth of at least 24% (at least $279 million).
Price Impact
More from AXGN